ARCHIVES

Going private may allow US Oncology to restructure, respond to Medicare cuts; equity investment firm offers to purchase shares.

This article is from The Cancer Letter archive.

Vol. 30 No. 17 | April 23, 2004

Download PDF Visit The Full Archive

Related Articles

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

CAP Issues Active Surveillance Guidance For Prostate Cancer

September 5, 2014

Robert Weinburger, Ernst Wynder Win Top Milken Awards

November 2, 1990

Gene Therapy Experiments Get RDAC Okay

August 10, 1990

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987

Kerrie Wilson Succeeds Alan Davis As ACS Chief Lobbyist

November 26, 1993